Germ cell tumours (GCT) comprise exquisitely chemosensitive neoplasms, and cure is possible in patients presenting with a high metastatic tumour burden. For the few patients with high-risk disease or who relapse after first-line chemotherapy, the administration of a tandem or a triple course of high-dose chemotherapy (HDCT) with carboplatin and etoposide with stem cell support may represent a valuable therapeutic option. From November 1981 to December 2015, 1179 patients aged ⩾40 years were identified from a total of 5295 registered patients (22%) from 226 EBMT centres.the present data may aid physicians who are treating advanced GCT to improve their knowledge of the mortality-rate after HDCT administration in older patients. HDCT can be safely administered in these high-risk patients and still represents their first therapeutic option in the salvage setting, pending prospective validation through clinical trials.
Necchi A., Lo Vullo S., Rosti G., Badoglio M., Giannatempo P., Raggi D., et al. (2017). Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: A retrospective study from the European Society for Blood and Marrow Transplantation database. BONE MARROW TRANSPLANTATION, 52(8), 1218-1220 [10.1038/bmt.2017.106].
Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: A retrospective study from the European Society for Blood and Marrow Transplantation database
Lanza F.Penultimo
Project Administration
;
2017
Abstract
Germ cell tumours (GCT) comprise exquisitely chemosensitive neoplasms, and cure is possible in patients presenting with a high metastatic tumour burden. For the few patients with high-risk disease or who relapse after first-line chemotherapy, the administration of a tandem or a triple course of high-dose chemotherapy (HDCT) with carboplatin and etoposide with stem cell support may represent a valuable therapeutic option. From November 1981 to December 2015, 1179 patients aged ⩾40 years were identified from a total of 5295 registered patients (22%) from 226 EBMT centres.the present data may aid physicians who are treating advanced GCT to improve their knowledge of the mortality-rate after HDCT administration in older patients. HDCT can be safely administered in these high-risk patients and still represents their first therapeutic option in the salvage setting, pending prospective validation through clinical trials.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
